$67.87 +1.30 (%) AbbVie Inc - NYSE

Dec. 18, 2014 | 10:40 AM

Partner Headlines

  1. These 2 Biotech Stocks Are Set To Split The $15 Billion Hepatitis C Market

    Benzinga | Dec. 12, 2014 | 11:44AM EST
  2. T Rowe Price's Top Stakes for the Third Quarter

    GuruFocus | Dec. 9, 2014 | 10:16AM EST
  3. Andreas Halvorsen Joins Other Gurus in Investing in Alibaba

    GuruFocus | Dec. 3, 2014 | 15:38PM EST
  4. Meet 5 Top Drug Stocks That Are Bolting Past Market

    IBD | Dec. 2, 2014 | 08:02AM EST
  5. Top 4 Stocks In The Drug Manufacturers-Major Industry With The Highest Operating Margin

    Benzinga | Dec. 2, 2014 | 04:38AM EST
  6. 5 Stock-Moving Medtech Events This December

    IBD | Nov. 28, 2014 | 14:18PM EST
  7. Six High-Yielding Mega-Cap Stocks

    GuruFocus | Nov. 25, 2014 | 17:22PM EST
  8. Fast Money Halftime Report Final Trade From November 24

    Benzinga | Nov. 24, 2014 | 20:26PM EST
  9. Can Partnering To Fight Hepatitis C Pay At Entanta?

    IBD | Nov. 24, 2014 | 16:44PM EST
  10. Can Partnering To Fight Hepatitis C Pay At Enanta?

    IBD | Nov. 24, 2014 | 16:44PM EST
  11. Dividend Aristocrats In Focus Part 45: AbbVie

    GuruFocus | Nov. 24, 2014 | 16:13PM EST
  12. John Paulson's Top 5 New Holdings For Q3

    GuruFocus | Nov. 21, 2014 | 22:08PM EST
  13. Pharma drugs advance in EU

    IBD | Nov. 21, 2014 | 18:19PM EST
  14. AbbVie, Celgene, Sanofi Drugs Get EU Endorsements

    IBD | Nov. 21, 2014 | 12:28PM EST
  15. Facebook Among New Holdings in Steve Mandel's Portfolio

    GuruFocus | Nov. 20, 2014 | 16:15PM EST
  16. Jeff Auxier Buys Berkshire Hathaway in Third Quarter

    GuruFocus | Nov. 18, 2014 | 16:33PM EST
  17. Five Ethical Drugmakers Keep Leadership Positions

    IBD | Nov. 17, 2014 | 18:27PM EST
  18. Will IPOs WhiteWave, Enanta Surpass Buy Points?

    IBD | Nov. 17, 2014 | 18:27PM EST
  19. Stocks Hitting 52-Week Highs

    Benzinga | Nov. 17, 2014 | 10:18AM EST
  20. Deutsche Bank Initiates Coverage On AbbVie

    Benzinga | Nov. 14, 2014 | 12:08PM EST
  21. Benzinga's Top Initiations

    Benzinga | Nov. 14, 2014 | 09:13AM EST
  22. Deutsche Bank Initiates AbbVie With Buy

    Benzinga | Nov. 14, 2014 | 08:10AM EST
  23. Shire CEO Looks Ahead To Independent Future

    IBD | Nov. 10, 2014 | 16:46PM EST
  24. Merck Down On Hepatitis C Data; Gilead Rises

    IBD | Nov. 10, 2014 | 11:14AM EST
  25. #PreMarket Primer: Monday, November 3: Commercial Space Travel Questioned After Failed Flights

    Benzinga | Nov. 3, 2014 | 07:55AM EST
  26. Humira Lifts AbbVie Earnings

    IBD | Oct. 31, 2014 | 19:03PM EST
  27. Investors Rewarded With Treats, Not Tricks, As Dow And S&P Close At Records High

    Benzinga | Oct. 31, 2014 | 16:54PM EST
  28. AbbVie Beats Q3 Earnings Estimates, Raises Guidance

    IBD | Oct. 31, 2014 | 14:25PM EST
  29. Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal

    IBD | Oct. 31, 2014 | 11:17AM EST
  30. UPDATE: AbbVie Posts Stronger-Than-Expected Q3 Results, Lifts Outlook

    Benzinga | Oct. 31, 2014 | 08:52AM EST
  31. #PreMarket Primer: Friday, October 31: BOJ Spooked By Lackluster Growth And Inflation

    Benzinga | Oct. 31, 2014 | 08:15AM EST
  32. Earnings Scheduled For October 31, 2014

    Benzinga | Oct. 31, 2014 | 05:13AM EST
  33. Amgen Refuses To Split, But Plans Hearten Investors

    IBD | Oct. 28, 2014 | 14:18PM EST
  34. Receptos Soars After Lead Drug Racks Up Another Win

    IBD | Oct. 28, 2014 | 11:46AM EST
  35. Allergan Lifts Guidance; Valeant Suggests Higher Bid

    IBD | Oct. 27, 2014 | 12:17PM EST
  36. My 5 Favorite Stocks With Dividend Growth Of The Week

    GuruFocus | Oct. 27, 2014 | 12:09PM EST
  37. Shire: Who Needs AbbVie?

    IBD | Oct. 24, 2014 | 18:46PM EST
  38. Shire EPS Growth Accelerates, Stock Continues Rebound

    IBD | Oct. 24, 2014 | 11:12AM EST
  39. Gilead's Hep C Dream Drug Faces Demanding Investors

    IBD | Oct. 22, 2014 | 16:44PM EST
  40. Making Money With Charles Payne: 10/20/14

    FoxBusiness | Oct. 21, 2014 | 18:00PM EST
  41. Celgene Reports More Good Crohn's Disease Data

    IBD | Oct. 21, 2014 | 11:32AM EST
  42. #PreMarket Primer: Tuesday, October 21: China's Third Quarter Growth Disappoints

    Benzinga | Oct. 21, 2014 | 07:45AM EST
  43. Must Watch Stocks For October 21, 2014

    Benzinga | Oct. 21, 2014 | 04:04AM EST
  44. AbbVie Unveils $5 Billion Buyback; Blames U.S. For Failed Inversion

    Benzinga | Oct. 20, 2014 | 20:20PM EST
  45. Benzinga's M&A Chatter for Monday October 20, 2014

    Benzinga | Oct. 20, 2014 | 19:27PM EST
  46. ABBVIE

    IBD | Oct. 20, 2014 | 18:57PM EST
  47. Announcement Of Termination Of Proposed AbbVie And Shire Transaction

    Benzinga | Oct. 20, 2014 | 17:13PM EST
  48. Enanta Pharma Reports Update on Collaboration Deal with AbbVie: Will Not Exercise Option for Co-Development, Co. Received $57M Related to Signing, $95M in Milestones

    Benzinga | Oct. 20, 2014 | 16:56PM EST
  49. Celgene's Crohn's Disease Drug Hits Its Marks

    IBD | Oct. 20, 2014 | 11:16AM EST
  50. Benzinga's Weekend M&A Chatter

    Benzinga | Oct. 19, 2014 | 21:58PM EST
Trading Center